BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-6.2%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$20.6B
AUM Growth
+$20.6B
(-9.7%)
Cap. Flow
+$247M
Cap. Flow
% of AUM
1.2%
Top 10 Holdings %
Top 10 Hldgs %
83.49%
Holding
127
New
5
Increased
17
Reduced
7
Closed
5
Top Buys
| 1 |
Incyte
INCY
|
$117M |
| 2 |
Entrada Therapeutics
TRDA
|
$80.5M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$48.4M |
| 4 |
TSVT
2seventy bio
TSVT
|
$21.4M |
| 5 |
Travere Therapeutics
TVTX
|
$19.5M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$61.1M |
| 2 |
Fulgent Genetics
FLGT
|
$20.1M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
$12.9M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$11.5M |
| 5 |
Novavax
NVAX
|
$8.67M |
Sector Composition
| 1 | Healthcare | 98.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.25B | 35.27% | 46,893,364 -394,895 | -0.8% | -$61.1M |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $3.16B | 15.38% | 11,668,897 | – | – |
|
|
3
Incyte
INCY
$16.5B
| $2.47B | 12.01% | 33,618,063 +1,595,938 | +5% | +$117M |
|
4
Kodiak Sciences
KOD
$478M
| $1.24B | 6.06% | 14,681,304 | – | – |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $978M | 4.76% | 41,910,704 | – | – |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $673M | 3.28% | 7,620,494 | – | – |
|
7
Ascendis Pharma
ASND
$11.8B
| $611M | 2.97% | 4,541,604 | – | – |
|
8
argenx
ARGX
$43.6B
| $392M | 1.91% | 1,119,557 | – | – |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $207M | 1.01% | 1,409,784 | – | – |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $176M | 0.86% | 12,710,818 | – | – |
|
11
Kymera Therapeutics
KYMR
$2.95B
| $151M | 0.74% | 2,384,742 | – | – |
|
|
NVTA
12
DELISTED
Invitae Corporation
NVTA
| $151M | 0.73% | 9,873,488 | – | – |
|
13
AbCellera Biologics
ABCL
$1.25B
| $149M | 0.73% | 10,450,180 | – | – |
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $127M | 0.62% | 1,499,213 | – | – |
|
15
Prelude Therapeutics
PRLD
$68.5M
| $126M | 0.61% | 10,123,824 | – | – |
|
16
Legend Biotech
LEGN
$6.41B
| $116M | 0.56% | 2,489,003 +125,000 | +5% | +$5.83M |
|
17
Pacific Biosciences
PACB
$393M
| $111M | 0.54% | 5,444,963 | – | – |
|
|
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $97M | 0.47% | 3,314,765 +97,324 | +3% | +$2.85M |
|
19
Cerus
CERS
$251M
| $93.4M | 0.45% | 13,713,195 | – | – |
|
|
IGMS
20
DELISTED
IGM Biosciences
IGMS
| $92.6M | 0.45% | 3,156,102 | – | – |
|
21
Immunocore
IMCR
$1.62B
| $86.3M | 0.42% | 2,520,730 | – | – |
|
|
22
Travere Therapeutics
TVTX
$1.56B
| $82.8M | 0.4% | 2,669,054 +629,282 | +31% | +$19.5M |
|
|
23
Entrada Therapeutics
TRDA
$208M
| $80.5M | 0.39% | +4,704,419 | New | +$80.5M |
|
24
Heron Therapeutics
HRTX
$207M
| $74.2M | 0.36% | 8,131,678 | – | – |
|
|
AMRN
25
Amarin Corp
AMRN
$311M
| $71.3M | 0.35% | 21,169,805 -686,227 | -3% | -$2.31M |
|